The corresponding proportions for patients diagnosed with CLL/SLL in 2018-2021 ( N = 2641) were 54.3% and 15.9%, respectively, showing an increasing trend in the use of targeted therapies and a decreasing trend in the use of CIT.
← all excerpts
Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the US.
1
—
—